M-CENK

Phase 2Small molecule

IImmunityBio, Inc.

M-CENK is one of 81 small molecule programs targeting Platinum-resistant Ovarian Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Platinum-Resistant Ovarian CancerRecruiting

ImmunotherapyNot yet recruiting

Prostate CancerNot yet recruiting

Platinum-Resistant Ovarian CancerPhase 2

Recruiting

ImmunotherapyPhase 2

Not yet recruiting

Prostate CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

20 2

Talzenna

Pfizer

Phase 3

9 3

GM-CSF

YY-mAbs Therapeutics

Phase 3

8 4

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 5

Lupron

Radiation Therapy Oncology Group

Phase 3

6 6

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

5 7

Antibiotic Prophylaxis

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 8

M-CENK

IImmunityBio, Inc.

Phase 2

1 9

Trexall

Duragesic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Platinum-Resistant Ovarian Cancer

NCT06710288

Q2 2031

Phase 2Not yet recruiting

Immunotherapy

NCT06765902

Phase 2Not yet recruiting

Prostate Cancer

NCT06765954

Clinical

Trials by Indication[1]

Immunotherapy1 trial

Immunotherapy Before and After Surgery

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT06765902·20 enrolled

Prostate Cancer1 trial

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT06765954·20 enrolled

Platinum-resistant Ovarian Cancer1 trial

A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Recruiting·IImmunityBio, Inc.·Phase 2·NCT06710288·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for M-CENK. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — M-CENK compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for M-CENK. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IImmunityBio, Inc.

M-CENK

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2031

Trials by Indication[1]

Immunotherapy1 trial

Prostate Cancer1 trial

Platinum-resistant Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News